VistaGen Therapeutics Faces Securities Class Actions Over Alleged Misleading Fasedienol Clinical Claims

Allegations of Misleading Clinical Claims Cloud Vistagen’s Fasedienol Program

Vistagen Therapeutics faces multiple securities class action claims alleging the company misled investors about the prospects of its investigational pherine candidate fasedienol for the acute treatment of social anxiety disorder (SAD). Plaintiffs, through filings and reminders from several U.S. law firms, assert that the company’s public statements about prior PALISADE‑2 results and planned enhancements and operational changes to the PALISADE‑3 trial created an unwarranted impression that Phase 3 success was likely and that PALISADE‑3 amounted to a confirmatory study. The complaints allege those statements materially overstated the strength of PALISADE‑2 and downplayed risks of clinical failure.

The litigation raises questions about disclosure practices and the characterization of clinical data that are central to biopharmaceutical development. The firms contend Vistagen’s portrayal of PALISADE‑2 endpoints and outcomes “infected” the market during an extended class period and that subsequent revelations have harmed market participants who relied on the company’s assurances. In the biotech industry, such allegations commonly trigger heightened scrutiny from regulators, potential partners and contract research organizations, and can complicate ongoing trial conduct and patient recruitment if confidence in trial design or data integrity erodes.

The actions are at a preliminary stage: the class has not been certified and lead‑plaintiff motions are pending. Plaintiffs seek to recover alleged investor losses and to hold Vistagen accountable under federal securities laws; the litigation timeline may extend through the company’s continuing clinical activities, potentially overlapping with PALISADE‑3 milestones and regulatory interactions. Vistagen does not appear to have issued a substantive public response in the notices circulated by the law firms.

Other legal notices and deadlines

Three firms — Rosen Law Firm, DJS Law Group LLP and The Schall Law Firm — are actively soliciting potential class members who purchased Vistagen securities between April 1, 2024 and December 16, 2025. The firms remind affected shareholders that anyone wishing to move for lead‑plaintiff status must do so by March 16, 2026, while noting that appointment as lead plaintiff is not required to participate in any recovery.

Allegations and statutes cited

The complaints invoke Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b‑5, centering on claims that public statements and investor disclosures failed to accurately characterize PALISADE‑2 endpoints and results. The firms emphasize prompt action to preserve legal rights as the litigation proceeds.